These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 39205242)

  • 1. Antiviral Agents for Preventing Cytomegalovirus Disease in Recipients of Hematopoietic Cell Transplantation.
    Jaing TH; Wang YL; Chiu CC
    Viruses; 2024 Aug; 16(8):. PubMed ID: 39205242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation.
    Maffini E; Giaccone L; Festuccia M; Brunello L; Busca A; Bruno B
    Expert Rev Hematol; 2016 Jun; 9(6):585-96. PubMed ID: 27043241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.
    Lin A; Maloy M; Su Y; Bhatt V; DeRespiris L; Griffin M; Lau C; Proli A; Barker J; Shaffer B; Giralt SA; Jakubowski AA; Papadopoulos EB; Papanicolaou GA; Seo SK; Perales MA
    Transpl Infect Dis; 2019 Dec; 21(6):e13187. PubMed ID: 31585500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refractory/Resistant Cytomegalovirus Infection in Transplant Recipients: An Update.
    Royston L; Papanicolaou GA; Neofytos D
    Viruses; 2024 Jul; 16(7):. PubMed ID: 39066247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Perspectives on Letermovir and Maribavir for the Management of Cytomegalovirus Infection in Solid Organ Transplant Recipients.
    Razonable RR
    Drug Des Devel Ther; 2024; 18():3987-4001. PubMed ID: 39258274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
    Abate D; Cesaro S; Cofano S; Fiscon M; Saldan A; Varotto S; Mengoli C; Pillon M; Calore E; Biasolo MA; Cusinato R; Barzon L; Messina C; Carli M; Palù G
    Transplantation; 2012 Mar; 93(5):536-42. PubMed ID: 22314338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Vaccination of Hematopoietic Cell Transplantation Recipients Improves Protective CD8 T-Cell Immunotherapy of Cytomegalovirus Infection.
    Gergely KM; Podlech J; Becker S; Freitag K; Krauter S; Büscher N; Holtappels R; Plachter B; Reddehase MJ; Lemmermann NAW
    Front Immunol; 2021; 12():694588. PubMed ID: 34489940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in pharmacotherapies for cytomegalovirus infection: what is the current state of play?
    Monday LM; Keri V; Chandrasekar PH
    Expert Opin Pharmacother; 2024 Apr; 25(6):685-694. PubMed ID: 38717943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
    Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
    J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection.
    Locatelli F; Bertaina A; Bertaina V; Merli P
    Expert Rev Hematol; 2016 Nov; 9(11):1093-1105. PubMed ID: 27690683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy.
    Hakki M
    Curr Hematol Malig Rep; 2020 Apr; 15(2):90-102. PubMed ID: 31981100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
    Jung S; Michel M; Stamminger T; Michel D
    BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on cytomegalovirus in transplant recipients: new agents, prophylaxis, and cell-mediated immunity.
    Manuel O; Avery RK
    Curr Opin Infect Dis; 2021 Aug; 34(4):307-313. PubMed ID: 34074879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CMV Infection in Hematopoietic Stem Cell Transplantation: Prevention and Treatment Strategies.
    Jakharia N; Howard D; Riedel DJ
    Curr Treat Options Infect Dis; 2021; 13(3):123-140. PubMed ID: 34305463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of cytomegalovirus-specific T cell responses in healthy volunteers and allogeneic stem cell recipients using vaccination with messenger RNA-transfected dendritic cells.
    Van Craenenbroeck AH; Smits EL; Anguille S; Van de Velde A; Stein B; Braeckman T; Van Camp K; Nijs G; Ieven M; Goossens H; Berneman ZN; Van Tendeloo VF; Verpooten GA; Van Damme P; Cools N
    Transplantation; 2015 Jan; 99(1):120-7. PubMed ID: 25050468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coinfection with Human Cytomegalovirus Genetic Variants in Transplant Recipients and Its Impact on Antiviral T Cell Immune Reconstitution.
    Smith C; Brennan RM; Tey SK; Smyth MJ; Burrows SR; Miles JJ; Hill GR; Khanna R
    J Virol; 2016 Aug; 90(16):7497-507. PubMed ID: 27279616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CMV prevention strategies in allogeneic hematopoietic cell transplantation; the role of prophylaxis and pre-emptive monitoring in the era of letermovir.
    Yong MK; Slavin MA; Chemaly RF; Papanicolaou GA
    Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14171. PubMed ID: 37864299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients.
    Avery RK; Marty FM; Strasfeld L; Lee I; Arrieta A; Chou S; Tatarowicz W; Villano S
    Transpl Infect Dis; 2010 Dec; 12(6):489-96. PubMed ID: 20682012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients.
    Valencia Deray KG; Danziger-Isakov LA; Downes KJ
    J Pediatric Infect Dis Soc; 2024 Feb; 13(Supplement_1):S14-S21. PubMed ID: 38417084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation.
    Zamora D; Duke ER; Xie H; Edmison BC; Akoto B; Kiener R; Stevens-Ayers T; Wagner R; Mielcarek M; Leisenring WM; Jerome KR; Schiffer JT; Finak G; De Rosa SC; Boeckh M
    Blood; 2021 Jul; 138(1):34-43. PubMed ID: 33657225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.